Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiomics Multifactorial Biomarker for Pulmonary Nodules

NCT03872362

Lung Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases +2 more

COMPLETED

The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages

NCT04005677

Pulmonary Nodule, Solitary Lung; Node

UNKNOWN

Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath

NCT06518655

Pulmonary Nodules, Multiple Pulmonary Nodules, Solitary Lung Cancer

RECRUITING

SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules

NCT06775587

Lung Cancer in Normal and Malignant Tumors

NOT_YET_RECRUITING

Early Adjuvant Diagnosis of Pulmonary Nodules Based on CTC.

NCT06187935

Pulmonary Nodules, Solitary Pulmonary Nodules, Multiple

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research design: It is planned to collect pulmonary nodules confirmed by preoperative CT during the period from January 2021 to June 2020 The peripheral blood and clinical information of 100 patients who underwent surgical operations were classified according to the pathological diagnosis of the patients It is the malignant pulmonary nodule group and the benign pulmonary nodule group. Through single-cell sequencing, flow cytometry analysis and radiomics The purpose of identifying the benign and malignant nature of pulmonary nodules is: ① To predict the benign and malignant nature of pulmonary nodules before surgery; ② Explore evil the differences in the immune microenvironment between patients with sexual and benign pulmonary nodules, and the search for specific markers with clinical value Object ③ Compare the diagnostic sensitivity of the new prediction method with that of traditional tumor markers and explore its role as a predictor The potential for measuring the benign and malignant nature of pulmonary nodules

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer (Diagnosis) Pulmonary Nodule Persistent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer

Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient underwent a ct examination
* Patient was confirmed to have pulmonary nodules
* Patient has been determined to undergo surgical treatment
* There are clear pathological results
* The clinicopathological data are complete

Exclusion Criteria

* Patient has no ct examination results
* Refuse surgical treatment
* Patient has no clear pathological diagnosis
* Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
* Patients with tumor emergencies that require immediate treatment.
* Poor vascular conditions.
* Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
* Patients with hematogenic infectious diseases, such as HBV.
* Patients with psychiatric disorders or severe mental illnesses.
* Patients who have difficulty communicating or are unable to be followed up for a long time

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes